汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
AbbVie’s emraclidine failed two phase 2 schizophrenia trials； FDA approves BridgeBio's Attruby to treat transthyretin amyloid cardiomyopathy (ATTR-CM); Intellia’s in vivo CRISPR therapy nex-z shows early promise in a phase 1 trial of ATTR-CM;
FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera, a HER2-directed biparatopic antibody, for unresectable or metastatic HER2-positive biliary tract cancer； Merck’s phase 3 trial of subcutaneous pembrolizumab with berahyaluronidase alfa demonstrates noninferior pharmacokinetics compared to intravenous Keytruda in adults with metastatic NSCLC； Eli Lilly removed the PD1 agonist program from its phase 2 RA pipeline; CAR T for SLE takes center stage at ACR 2024 (BMS’ CC97540, Kyverna’s KYV-101, Fate’s FT819); Amgen Presented Ph3 data of Uplizna for treatment of IgG4-related disease at ACR 2024;
Amgen's MariTide shows 20% weight loss, but dosing questions hang over its phase 2 readout; Viking Therapeutics presents phase 2b results of VK2809 in patients with biopsy-confirmed MASH, showing a best-in-class profile； Interim analysis of Novo Nordisk’s Semaglutide in a phase 3 MASH trial showed improvement in liver fibrosis without worsening of steatohepatitis; Boston Pharmaceuticals’ once-monthly injection efimosfermin alfa achieves promising rates of fibrosis improvement in a phase 2 MASH trial.
活动详情
主题：Monthly biotech news discussion - November 2024 in review
时间：2024年11月30日 Sat 8:00 PM（EST）/ 2024年12月01日 周日 早上9:00 AM（北京时间）
地点：药时代视频号
嘉宾：
Jimmy Wang (王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
Ethan Xu (徐亦迅),VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Stephen Yan (严顺飞), BD Search & Evaluation @ AstraZeneca
(https://www.linkedin.com/in/shunfei-yan/)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc
(http://linkedin.com/in/charlene-liao-a1872a55)
Sophia Su, Healthcare Investment @ Family Office
(http://linkedin.com/in/sophia-s-2a03951b5)
Xianbo Zhou (周显波), Founder & CEO @ AstraNeura
(https://www.linkedin.com/in/xianbo-zhou-7b33b76/)
Yong Zhang (张勇), Director @ Intellia Therapeutics,Inc
(https://www.linkedin.com/in/yongzhang7/)
Ning Wang (王宁), Senior Bioinformatics Scientist @ Arcus Biosciences
(https://www.linkedin.com/in/nwangucla/)
Han Ying (英函), CEO@Gyre Therapeutics
(https://www.linkedin.com/in/han-ying-6128b6334?trk=contact-info)
Zhiyong Yang (杨志勇), Scientific Director @ Novo Nordisk
(https://www.linkedin.com/in/zhiyong--yang)
Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Jun Wang & Ethan Xu
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
BioSpark events Calendar:
https://tinyurl.com/tcwy44t6
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
封面图来源：123rf
2024-11-28
2024-11-28
2024-11-27
版权声明/免责声明
本文为授权转载文章。
本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。
文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。
如有任何问题，请与我们联系。
衷心感谢!
药时代官方网站:www.drugtimes.cn
联系方式:
电话:13651980212
微信:27674131
邮箱:contact@drugtimes.cn
点击这里，报名参加行业盛会！
